Joel W Neal, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Neal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A111199 · Current
Licensed to practise in California · since 2010 · expires 2027-08-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$114,410
Medicare paid this office $114,410 for 248 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 96 | $35,920 | $170 |
| Long return visit (40+ min) | 95 | $34,958 | $127 |
| Return visit (30+ min) | 73 | $13,363 | $121 |
| Return visit (30+ min) | 77 | $9,376 | $82 |
| New patient visit (60+ min) | 35 | $5,443 | $156 |
See all 8 services
| Long return visit (40+ min) | 96 | $35,920 | $170 |
| Long return visit (40+ min) | 95 | $34,958 | $127 |
| Return visit (30+ min) | 73 | $13,363 | $121 |
| Return visit (30+ min) | 77 | $9,376 | $82 |
| New patient visit (60+ min) | 35 | $5,443 | $156 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 109 | $3,670 | $15 |
| New patient visit (60+ min) | 15 | $2,930 | $195 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 92 | $2,651 | $15 |
Who their Medicare patients are
248 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 12% · Women 56% · Also on Medicaid 22% · Health risk score 2.64. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 75% · High blood pressure 67% · Coronary heart disease 27% · Chronic kidney disease 27% · COPD 25% · Diabetes 24% · Atrial fibrillation 22% · Heart failure 16% · Depression 14% · Stroke 14%.
The office billed $444,055, Medicare allowed $146,738 and paid $114,410; for 1,246 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 248 | 1,246 | 74 | 2.64 | $444,055 | $114,410 |
| 2023 | 256 | 906 | 75 | 2.49 | $415,653 | $107,696 |
| 2022 | 244 | 848 | 75 | 2.53 | $377,174 | $103,624 |
| 2021 | 234 | 834 | 74 | 2.56 | $380,688 | $98,570 |
| 2020 | 211 | 912 | 74 | 2.56 | $329,637 | $82,616 |
| 2019 | 246 | 995 | 74 | 2.71 | $171,689 | $90,171 |
| 2018 | 238 | 923 | 72 | 2.61 | $151,762 | $84,201 |
| 2017 | 224 | 837 | 72 | 2.41 | $198,700 | $76,391 |
| 2016 | 235 | 800 | 72 | 2.47 | $224,635 | $73,242 |
| 2015 | 221 | 823 | 72 | 2.47 | $229,341 | $74,703 |
| 2014 | 242 | 1,003 | 72 | 2.16 | $260,692 | $86,792 |
| 2013 | 179 | 793 | 72 | 2.13 | $200,039 | $65,025 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 158 | $69,816 | $130 |
| Return visit (30+ min) | 123 | $17,124 | $87 |
| New patient visit (60+ min) | 53 | $8,818 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,836 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,852 | $110 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,712 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,532 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $768 | $45 |
2022: 6 services
| Long return visit (40+ min) | 165 | $70,465 | $130 |
| Return visit (30+ min) | 83 | $11,776 | $89 |
| New patient visit (60+ min) | 52 | $8,789 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,558 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,400 | $185 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,179 | $98 |
2021: 5 services
| Long return visit (40+ min) | 151 | $60,964 | $129 |
| Return visit (30+ min) | 115 | $18,066 | $87 |
| New patient visit (60+ min) | 49 | $8,403 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,723 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,997 | $182 |
2020: 8 services
| Long return visit (40+ min) | 121 | $31,069 | $103 |
| Return visit (30+ min) | 139 | $26,995 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $7,947 | $98 |
| New patient visit (60+ min) | 39 | $6,050 | $155 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,793 | $200 |
| Return visit (30+ min) | 27 | $2,263 | $75 |
| Long return visit (40+ min) | 13 | $1,821 | $121 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,149 | $104 |
2019: 7 services
| Long return visit (40+ min) | 137 | $36,031 | $97 |
| Return visit (30+ min) | 124 | $25,627 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,150 | $94 |
| New patient visit (60+ min) | 57 | $8,240 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,772 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,782 | $66 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,190 | $99 |
2018: 6 services
| Long return visit (40+ min) | 138 | $38,369 | $99 |
| Return visit (30+ min) | 112 | $22,622 | $67 |
| New patient visit (60+ min) | 61 | $9,038 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $4,775 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,366 | $182 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,284 | $99 |
2017: 6 services
| Long return visit (40+ min) | 108 | $26,719 | $98 |
| Return visit (30+ min) | 99 | $22,164 | $68 |
| New patient visit (60+ min) | 77 | $11,455 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $7,976 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,263 | $181 |
| Hospital discharge day management, 30 minutes or less | 11 | $729 | $66 |
2016: 7 services
| Long return visit (40+ min) | 107 | $22,068 | $99 |
| Return visit (30+ min) | 101 | $21,905 | $69 |
| New patient visit (60+ min) | 72 | $10,618 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $6,852 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,023 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,993 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,944 | $121 |
2015: 7 services
| Return visit (30+ min) | 101 | $22,589 | $68 |
| Long return visit (40+ min) | 101 | $22,319 | $99 |
| New patient visit (60+ min) | 67 | $9,868 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $7,891 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,235 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,196 | $65 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,560 | $97 |
2014: 7 services
| Return visit (30+ min) | 116 | $36,276 | $68 |
| Long return visit (40+ min) | 91 | $17,491 | $95 |
| New patient visit (60+ min) | 100 | $15,044 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,562 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,497 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,754 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,582 | $122 |
2013: 6 services
| Return visit (30+ min) | 91 | $27,837 | $64 |
| Long return visit (40+ min) | 77 | $13,790 | $94 |
| New patient visit (60+ min) | 63 | $8,864 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $5,946 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,845 | $175 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,608 | $95 |
Medicaid work
$6,955 in 2024
Medicaid paid $6,955 for 84 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 70 | $6,311 |
| Return visit (30+ min) | 14 | $645 |
| 2024 | 84 | 2 | 17 | $6,955 |
| 2023 | 360 | 3 | 26 | $15,040 |
| 2022 | 121 | 2 | 20 | $4,507 |
| 2021 | 120 | 4 | 15 | $6,732 |
| 2020 | 101 | 2 | 16 | $3,650 |
| 2019 | 91 | 3 | 17 | $3,444 |
| 2018 | 12 | 1 | 12 | $553 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 234 | $10,123 |
| Return visit (30+ min) | 110 | $3,936 |
| 1ST HOSP IP/OBS HIGH 75 | 16 | $980 |
2022
| Long return visit (40+ min) | 78 | $2,914 |
| Return visit (30+ min) | 43 | $1,593 |
2021
| 1ST HOSP IP/OBS HIGH 75 | 16 | $2,022 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $2,022 |
| Long return visit (40+ min) | 57 | $2,011 |
| Return visit (30+ min) | 18 | $678 |
2020
| Return visit (30+ min) | 66 | $2,478 |
| Long return visit (40+ min) | 35 | $1,172 |
2019
| Return visit (30+ min) | 66 | $2,230 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $646 |
| Long return visit (40+ min) | 13 | $568 |
2018
| Long return visit (40+ min) | 12 | $553 |
Drugs they prescribed that Part D paid
$464,638
Pharmacies billed $464,638 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
92 generic and 31 brand-name prescriptions · $464,638 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 24 | $390,412 | $16,267 |
| Rosuvastatin | 11 | $666 | $61 |
| Prochlorperazine Maleate | 12 | $90 | $8 |
Year by year
| 2024 | 123 | 47 | None | 25% | $464,638 |
| 2023 | 200 | 57 | None | None | $969,078 |
| 2022 | 140 | 40 | None | 32% | $650,124 |
| 2021 | 93 | 38 | None | 40% | $550,093 |
| 2020 | 246 | 58 | None | 39% | $1,052,682 |
| 2019 | 332 | 77 | 4% (12) | 43% | $1,641,856 |
| 2018 | 395 | 88 | None | 46% | $2,120,653 |
| 2017 | 440 | 86 | None | None | $1,743,292 |
| 2016 | 460 | 86 | 3% (14) | 51% | $1,770,084 |
| 2015 | 447 | 81 | 4% (17) | None | $771,406 |
| 2014 | 513 | 80 | 6% (31) | None | $477,395 |
| 2013 | 543 | 74 | 4% (21) | None | $186,768 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Tagrisso | 37 | $621,684 | $16,802 |
2022: 1 drug
| Tagrisso | 20 | $336,048 | $16,802 |
2021: 1 drug
| Tagrisso | 24 | $412,504 | $17,188 |
2020: 8 drugs
| Tagrisso | 34 | $527,082 | $15,502 |
| Xalkori | 12 | $224,304 | $18,692 |
| Lorbrena | 11 | $179,702 | $16,337 |
| Ondansetron | 16 | $276 | $17 |
| Prochlorperazine Maleate | 20 | $275 | $14 |
| Dexamethasone | 14 | $249 | $18 |
| Levothyroxine | 11 | $200 | $18 |
| Prednisone | 17 | $107 | $6 |
2019: 7 drugs
| Tagrisso | 81 | $1,253,782 | $15,479 |
| Xalkori | 14 | $247,696 | $17,693 |
| Dexamethasone | 18 | $303 | $17 |
| Levothyroxine | 13 | $277 | $21 |
| Prednisone | 24 | $186 | $8 |
| Ondansetron | 17 | $178 | $10 |
| Prochlorperazine Maleate | 16 | $174 | $11 |
2018: 9 drugs
| Tagrisso | 77 | $1,154,577 | $14,995 |
| Tarceva | 35 | $274,877 | $7,854 |
| Xalkori | 15 | $252,775 | $16,852 |
| Alecensa | 14 | $201,366 | $14,383 |
| Ondansetron | 20 | $256 | $13 |
| Dexamethasone | 12 | $127 | $11 |
| Lorazepam | 19 | $83 | $4 |
| Prochlorperazine Maleate | 12 | $60 | $5 |
| Omeprazole | 16 | $59 | $4 |
2017: 8 drugs
| Tarceva | 75 | $569,712 | $7,596 |
| Xalkori | 33 | $519,803 | $15,752 |
| Tagrisso | 29 | $404,586 | $13,951 |
| Ondansetron | 34 | $794 | $23 |
| Dexamethasone | 28 | $401 | $14 |
| Prochlorperazine Maleate | 14 | $105 | $8 |
| Ondansetron Odt | 11 | $94 | $9 |
| Lorazepam | 28 | $78 | $3 |
2016: 10 drugs
| Tagrisso | 53 | $705,416 | $13,310 |
| Tarceva | 96 | $651,077 | $6,782 |
| Xalkori | 25 | $385,076 | $15,403 |
| Entecavir | 11 | $10,331 | $939 |
| Enoxaparin | 18 | $6,887 | $383 |
| Clindamycin Phosphate | 11 | $837 | $76 |
| Dexamethasone | 22 | $175 | $8 |
| Ondansetron | 19 | $162 | $9 |
| Prochlorperazine Maleate | 20 | $150 | $7 |
| Lorazepam | 27 | $125 | $5 |
2015: 7 drugs
| Tarceva | 88 | $539,484 | $6,130 |
| Xalkori | 12 | $159,329 | $13,277 |
| Dexamethasone | 48 | $531 | $11 |
| Ondansetron | 27 | $304 | $11 |
| Prochlorperazine Maleate | 34 | $198 | $6 |
| Gabapentin | 11 | $131 | $12 |
| Lorazepam | 17 | $81 | $5 |
2014: 9 drugs
| Tarceva | 75 | $453,557 | $6,047 |
| Clindamycin Phosphate | 18 | $1,292 | $72 |
| Hydrocodone-Acetaminophen | 15 | $501 | $33 |
| Ondansetron | 39 | $468 | $12 |
| Dexamethasone | 39 | $317 | $8 |
| Prochlorperazine Maleate | 38 | $224 | $6 |
| Ondansetron Odt | 13 | $156 | $12 |
| Lorazepam | 20 | $116 | $6 |
| Citalopram Hbr | 16 | $68 | $4 |
2013: 15 drugs
| Tarceva | 26 | $136,531 | $5,251 |
| Enoxaparin | 12 | $17,127 | $1,427 |
| Advair Diskus | 11 | $2,849 | $259 |
| Clindamycin Phosphate | 29 | $1,702 | $59 |
| Combigan | 14 | $1,337 | $96 |
| Nystatin | 16 | $797 | $50 |
| Hydrocodone-Acetaminophen | 21 | $502 | $24 |
| Megestrol Acetate | 11 | $392 | $36 |
| Ondansetron | 23 | $373 | $16 |
| Gabapentin | 11 | $292 | $27 |
| Dexamethasone | 34 | $269 | $8 |
| Prochlorperazine Maleate | 34 | $253 | $7 |
| Lorazepam | 38 | $203 | $5 |
| Anastrozole | 11 | $173 | $16 |
| Zolpidem | 11 | $71 | $6 |
Money from drug and device companies
$37,752 in 2025
| 2025 | 10 | 25 | $37,151 | $37,752 |
| 2024 | 13 | 42 | $72,810 | $73,791 |
| 2023 | 9 | 18 | $16,571 | $17,735 |
| 2022 | 10 | 14 | $30,658 | $30,989 |
| 2021 | 7 | 10 | $23,084 | $23,084 |
| 2020 | 3 | 3 | $11,174 | $11,174 |
| 2019 | 2 | 6 | $3,100 | $4,115 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Iovance Biotherapeutics | Amtagvi | $10,875 | 3 payments
|
| Taiho Oncology | None | $5,984 | 4 payments
|
| Janssen Biotech | Rybrevant | $5,810 | 8 payments
|
| Janssen Scientific Affairs | Rybrevant | $4,650 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $3,005 | 2 payments
|
| Eli Lilly and | None | $2,790 | 2 payments
|
See all 25 published payments
| Janssen Biotech | Consulting · 2025-12-18 | Rybrevant | $626 |
| Janssen Biotech | Consulting · 2025-12-11 | Rybrevant | $1,670 |
| Taiho Oncology | Consulting · 2025-11-12 | None | $390 |
| Taiho Oncology | Consulting · 2025-11-12 | None | $2,340 |
| Janssen Scientific Affairs | Consulting · 2025-11-03 | Rybrevant | $2,325 |
| Genentech USA | Consulting · 2025-10-16 | Tecentriq | $760 |
| Eli Lilly and | Consulting · 2025-09-15 | None | $1,800 |
| Pfizer | Meals · 2025-09-07 | Braftovi | $58 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-08-06 | Tagrisso | $2,870 |
| Taiho Oncology | Consulting · 2025-07-01 | None | $3,120 |
| Janssen Biotech | Consulting · 2025-06-30 | Rybrevant | $1,620 |
| Eli Lilly and | Consulting · 2025-06-23 | None | $990 |
| Iovance Biotherapeutics | Consulting · 2025-06-17 | Amtagvi | $2,625 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-01 | Datroway | $135 |
| Taiho Oncology | Meals · 2025-05-30 | None | $134 |
| Janssen Biotech | Meals · 2025-05-29 | Rybrevant | $94 |
| Janssen Biotech | Meals · 2025-05-29 | Rybrevant | $14 |
| Iovance Biotherapeutics | Consulting · 2025-04-24 | Amtagvi | $3,750 |
| Janssen Scientific Affairs | Consulting · 2025-04-16 | Rybrevant | $2,325 |
| Janssen Biotech | Meals · 2025-04-01 | Rybrevant | $15 |
| Boehringer Ingelheim Pharmaceuticals | Consulting · 2025-03-25 | None | $2,220 |
| Janssen Biotech | Consulting · 2025-03-13 | Rybrevant | $1,620 |
| Janssen Biotech | Meals · 2025-02-20 | Rybrevant | $150 |
| GlaxoSmithKline | Consulting · 2025-01-30 | None | $1,600 |
| Iovance Biotherapeutics | Consulting · 2025-01-22 | Amtagvi | $4,500 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $73,791
| Iovance Biotherapeutics | Amtagvi | $13,875 | 9 payments
|
| Amgen | Nplate | $12,485 | 2 payments
|
| Abbvie | None | $11,269 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $10,094 | 9 payments
|
| Janssen Scientific Affairs | None | $7,800 | 5 payments
|
| Boehringer Ingelheim International GmbH | None | $4,810 | 1 payment
|
| Eli Lilly and | Retevmo | $4,616 | 3 payments
|
| Janssen Biotech | Rybrevant | $2,965 | 3 payments
|
| Gilead Sciences | None | $2,870 | 1 payment
|
| GlaxoSmithKline | None | $1,600 | 1 payment
|
| Daiichi Sankyo | Enhertu | $702 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $650 | 1 payment
|
| Genentech USA | Alecensa | $55 | 1 payment
|
2023: $17,735
| Gilead Sciences | Trodelvy | $6,729 | 8 payments
|
| Novocure GmbH | None | $4,770 | 1 payment
|
| Abbvie | None | $3,600 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,330 | 2 payments
|
| Amgen | Nplate | $861 | 1 payment
|
| Novocure | None | $153 | 2 payments
|
| Genentech USA | Tecentriq | $116 | 1 payment
|
| Exelixis | None | $105 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $71 | 1 payment
|
2022: $30,989
| Amgen | Nplate | $7,672 | 3 payments
|
| Genzyme | Libtayo | $7,353 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Exkivity | $6,750 | 2 payments
|
| Gilead Sciences | None | $2,570 | 1 payment
|
| Genentech USA | Tecentriq | $2,200 | 1 payment
|
| Janssen Scientific Affairs | Rybrevant | $2,170 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $1,965 | 1 payment
|
| Exelixis | Cabometyx | $157 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $123 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $30 | 1 payment
|
2021: $23,084
| Takeda Pharmaceuticals U.S.A. | Exkivity | $9,540 | 3 payments
|
| Regeneron Pharmaceuticals | Libtayo | $3,635 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $2,620 | 1 payment
|
| Genzyme | Libtayo | $2,289 | 1 payment
|
| Amgen | Nplate | $2,200 | 1 payment
|
| Blueprint Medicines | None | $1,400 | 1 payment
|
| Eli Lilly and | None | $1,400 | 1 payment
|
2020: $11,174
| Eli Lilly and | None | $7,700 | 1 payment
|
| Amgen | Nplate | $1,930 | 1 payment
|
| Blueprint Medicines | None | $1,544 | 1 payment
|
2019: $4,115
| Genentech USA | Alecensa | $4,029 | 5 payments
|
| Novartis Pharmaceuticals | Inc280 | $87 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2025 | Their institution | $1,130,135 |
| Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2020 | Their institution | $494,484 |
| AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2022 | Their institution | $400,705 |
| Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2023 | Their institution | $392,166 |
| Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2019 | Their institution | $353,981 |
| Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Sm · 2021 | Their institution | $327,699 |
| Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2022 | Their institution | $325,105 |
| Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2021 | Their institution | $294,259 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2023 | Their institution | $241,824 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022 | Their institution | $235,370 |
| AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2023 | Their institution | $211,630 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2020 | Their institution | $200,617 |
| AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2021 | Their institution | $197,479 |
| E.R. Squibb & Sons, L.L.C. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2023 | Their institution | $141,504 |
| AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2024 | Their institution | $123,837 |
| Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2024 | Their institution | $117,737 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2025 | Their institution | $114,942 |
| Exelixis Inc. · Xl184-Ctep-E1512 · 2022 | Their institution | $104,000 |
| GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2021 | Their institution | $85,046 |
| Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2024 | Their institution | $79,381 |
| E.R. Squibb & Sons, L.L.C. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2024 | Their institution | $64,856 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2024 | Their institution | $52,918 |
| GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2022 | Their institution | $52,369 |
| Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2025 | Their institution | $51,025 |
| GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2020 | Their institution | $50,352 |
| Exelixis Inc. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2024 | Their institution | $47,667 |
| Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2024 | Their institution | $35,194 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2021 | Their institution | $33,078 |
| Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2023 | Their institution | $31,354 |
| ABBVIE INC. · An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With Ptk7-Expressing, Recurrent Non-Small Cell Lung Cancer · 2022 | Their institution | $30,733 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2021 | Their institution | $28,213 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2024 | Their institution | $25,641 |
| AstraZeneca UK Limited · Tagrisso Testing Tx Patterns Rwo Early Stage Nsclc · 2024 | Their institution | $20,400 |
| Genentech, Inc. · Atezolizumab Cabozantinib Vs Docetaxel in Metastatic Nsclc Previously Treated With Cpi Chemo · 2024 | Their institution | $12,745 |
| GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2024 | Their institution | $11,985 |
| AstraZeneca UK Limited · Tagrisso Testing Tx Patterns Rwo Early Stage Nsclc · 2023 | Their institution | $10,010 |
| Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2023 | Their institution | $5,279 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2022 | Their institution | $4,377 |
| GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2023 | Their institution | $2,776 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2023 | Their institution | $2,703 |
| ABBVIE INC. · A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (Abbv-647, A Ptk7-Targeting Antibody Drug Conjugate) in Subjects With Ptk7-Expressing, Recurrent Non-Small Cell Lung Cancer · 2021 | Their institution | $773 |
| F. Hoffmann-La Roche AG · Atezolizumab Cabozantinib Vs Docetaxel in Metastatic Nsclc Previously Treated With Cpi Chemo · 2023 | This clinician | $638 |
| ViiV Healthcare Company · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2022 | Their institution | $576 |
| Eli Lilly and Company · A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected Or Unresectable Kras G12c-Mutant, Non-Small Cell Lung Cancer - Sunray-02 · 2025 | Their institution | $478 |
| Novartis Pharmaceuticals Corporation · A Phase II Multi Center Open Label Single Arm Study To Evaluate the Efficacy and Safety of Oral Ldk378 Treatment for Patients With Alk Rearranged Non Small Cell Lung Cancer Metastatic To the Brain · 2021 | Their institution | $230 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Study of Canakinumab + Pembrolizumab Alone As Maintenace Therapy Following Chemotherapy + Pembrolizumab Induction Therapy in Previously Untreated Adult Patients With Stage Iiib Or IV Non-Small Cell Lung Cancer. · 2019 | Their institution | $181 |
| Merck Sharp & Dohme LLC · A Phase II,III Randomized Trial of Two Doses of Mk-3475 Sch 900475 Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer · 2022 | Their institution | $91 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Study of Canakinumab + Pembrolizumab Alone As Maintenace Therapy Following Chemotherapy + Pembrolizumab Induction Therapy in Previously Untreated Adult Patients With Stage Iiib Or IV Non-Small Cell Lung Cancer. · 2020 | Their institution | $65 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790858942
- Licence
- CA A111199, MA 230363California A111199: Current · expires 2027-08-31
- Trained
- Northwestern University Feinberg Medical School, 2004
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-16
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 875 Blake Wilbur Dr, Stanford, CA, 94305